Ora

FACT SHEET

Inspiring the Future of Ophthalmic Clinical Development

OraNet™

Building global relationships to enhance clinical success

OraNet™ is our ophthalmic clinical research site network, comprised of Alliance Sites & Proven Ophthalmic Performers. Together, these two categories of elite sites offer sponsors access to industry-leading investigative partners prepared to prioritize the success of their studies.

Alliance Partners, representing our closest partnerships, agree to prioritize our trials, ensuring patient participation without competition from other studies.

Proven Ophthalmic Performers have extensive experience and in-depth understanding of their capabilities, consistently delivering exceptional results.

Together, OraNet™ Alliance Partners and Proven Ophthalmic Performers exemplify our commitment to excellence and efficiency in clinical research, providing sponsors with optimal patient recruitment, study performance, and high-quality data for their ophthalmic trials.

1000+ global research sites in various ophthalmic disciplines ensures consistent, high-quality data

Feasibility, Site Selection, and Protocol Training

Selecting the Right Sites → **Extensive Site Training** → **Continued Excellence**

OraNet™ allows our sponsors to accelerate study start-up timelines by leveraging our site relationships to expedite feasibility, site-selection, and kickstart protocol training.

- Strategically select the right sites that are not overutilized on completing trials.
- Leverage historical performance information and pre-collected feasibility to evaluate site capacity for each study protocol.
- OraNet™ sites are extensively trained and supported by our in-house clinical trial specialists & physicians who work closely with each site to instruct investigators and staff before the start of each new protocol.
- Collaborate with our sites to ensure efficient and consistent execution across the entire study timeline, ensuring strict protocol adherence.

OraNet™ Alliance Partners: Supercharging enrollment for your trial

Alliance Partners: Unique partnerships with exclusive or priority access for Ora studies that receive support from our dedicated Site Partners Solutions Team.

Becoming an OraNet™ Alliance Partner provides clinical research sites with access to our extensive experience in ophthalmology trials, supporting them to excel in patient enrollment and study performance. Through tailored training and recruitment strategies, partners receive practical assistance for successful research outcomes.

By joining the Ora network, partners benefit from collaborative support aimed at advancing ophthalmic research. With personalized guidance, they navigate research complexities effectively, contributing meaningfully to improving ocular health.

> **"I wholeheartedly urge anyone serious in becoming a Clinical Trial Site or elevating their current Clinical Trial exposure to consider joining the OraNet™ Alliance."**
>
> **Dr. Gary W. Jerkins,** Advancing Vision Research

3x Faster Enrollment in Anterior Segment Studies

In 2023 Anterior studies, OraNet™ Alliance sites enrolled an average of >200% more patients per site than non-Alliance sites.

40-60% Faster Enrollment in Posterior Segment Studies

OraNet™ sites enroll, on average, 40-60% more patients on current retina programs compared to non-OraNet™ sites.

Unlock your site's full clinical trial potential and be part of some of the most exciting clinical innovation in ophthalmology by joining the OraNet™ Alliance network.

SiteSolutions@oraclinical.com

A Global Network of Sites for High Quality Data, anywhere in the world

Our localized support teams in North and South America, Europe, Asia, and Australia offer customized assistance, understanding each community's specific needs. We fast-track contracting via global alliances, simplifying the start-up process in diverse regulatory landscapes. We also ensure uniformity in global studies by cross-training at our international clinical sites.

Buenos Aires, Argentina

Background: Phase 2 Global Interventional Retina Trial, First in Human. Ora: Managed sites outside of US (Latam and EU). Utilized Alliance partnerships in Argentina.

Activation: Approved in parallel with Europe, 6-weeks behind US. Argentina first country outside the United States to enroll patients.

Performance: Argentina closed enrollment for study in 2 weeks with a recruitment rate of 12x the US site average (0.27 pts/site/month vs. 3.33 pts/site/month). The top Argentinian site was the second top enroller globally for this study.

Qingdao, China

Background: A global phase 3 global pediatric myopia study.

Performance: The strongest enrolling sites for the study were in China with an enrollment rate of 1.35 patients per site per month with extremely high levels of patient trial adherence with 5.9% drop out rate compared to a global study average of 10%.

Qindgao Eye Hospital ranked number 2 across all 48 study sites.

Dublin, Republic of Ireland

Background: A global myopia trial across Europe, the United States, and Asia.

Activation: Contract and Negotiation completed faster than average in Europe.

Performance: Highest enrolling site on the study, successfully screened 60 patients at an enrollment rate of 5 subjects per month providing exceptionally high-quality data due to a dedicated research facility with a highly skilled research team.

Wilmington, NC, United States

Background: Academic sites caused delays during startup of a TED study.

Activation: Wilmington Eye activated within an impressive 6-week period, roughly twice as fast as non OraNet™ sites.

Performance: Post activation, Wilmington Eye contributed 100% of the study's enrollment since activation. The success can be attributed to effective communication, with Ora providing vital support to the site.

OraNet™ Case Study: Maximizing Your Clinical Research Potential

Through site development collaboration with Ora, OraNet™ was able to support Dr. Vollmer's training and site development to evolve from being research-naive to transforming into one of Ora's key ophthalmic partners, and Alliance site.

Example: Total vs Target Enrollment



Participated in > 25 Ora studies since 2017

7+ Phase 3 trials with 3 NDA approvals and clean inspections 2017

Dedicated research staff of 5+ trained study coordinators

Find out how Ora can supercharge your clinical research at oraclinical.com

OraNet™ Case Study: Supercharging Retina Enrollment

Retina site located in Fort Worth, Texas

Achieved highest enroller on first study as an Alliance Partner

Participated in 3x Ora Studies since joining OraNet™ in May 2023

Dedicated research staff of 11x trained personnel



Site Activation 1-2 Months Earlier through Alliance Partnerships

Our start-up process is tailored to expedite site activation and support sponsors throughout the process. With targeted start-up tools and remote check-ins, we swiftly address any potential problem areas, ensuring a smooth and efficient start to your trial. Our dedicated single point of contact serves as a reliable resource for all inquiries and challenges related to start-up, providing clarity and accessibility throughout the process. Additionally, we offer internal support for fast-track activation of partner sites when possible, facilitating timely trial initiation.

We assist with site qualification visits, offering additional support upon request. This includes providing required equipment lists, calibration trackers, and conducting mock site qualification sessions to ensure readiness. We offer best practice sessions for PIs and Clinical Research Coordinators, equipping them with the knowledge and tools needed for success.

By combining targeted tools, dedicated support, and comprehensive assistance, OraNet™ streamlines the start-up phase, empowering our partners to embark on their trials with confidence and efficiency.

Site Activation 1-2 Months Earlier Through OraNet™

What our sites say about Ora

"I would highly recommend Ora to other clinicians. Ora has proven to be an enthusiastic and highly effective partner. They have worked tirelessly to secure clinical trials for our site. They have worked hard to have our site ready and have us prepared for site meetings."

Dr. Armann Farr
Charlotte, NC, USA

"It is my number one choice and recommendation whenever discussing with biotechs their future plans. Having the primary endpoint in focus is something that we only have with Ora. Generic CROs most of the time have no idea what that means."

Dr. Patricio Schlottmann
Buenos Aires, Argentina

"Ora has a ton of experience in ophthalmology and many options for site support. I think their process is efficient and smooth and my experience is they know how to meet enrollment timelines even when they are tight."

Dr. Jamie Paauw
Lynchburg, VA, USA

100%
Ophthalmology

100%
Patient-focused

Ora

Ora is a global full-service ophthalmic drug and device development firm with vast capabilities through all steps of clinical research, including preclinical, clinical, CMC & regulatory, and patient and site evaluations. Through Ora's 40+ years of experience, the company has assisted in bringing more than 80 products to market. Ora's team of experts utilizes global regulatory strategies, integrated research operations, and extensive site and patient engagement to accelerate product development in anterior and posterior segment, as well as ophthalmic devices.